WebMay 20, 2013 · 6535. Background: Several randomized trials have shown that chemotherapy-free intervals (CFIs) may reduce toxicity without compromising survival … WebAim: Despite recent advances in the treatment of ovarian cancer, recurrence of the disease is still frequent. This study evaluated whether multiple lines of chemotherapy have impact on overall survival (OS), progression free survival (PFS) or on treatment free intervals (TFIs) after serial chemotherapy lines in recurrent settings. Methods: A total of 189 patients …
The ASCO Post
WebApr 14, 2024 · Toxicities were collected for each chemotherapy cycle. The interval between chemotherapy cycles was defined by the number of days between the first day of two consecutive cycles; for the last cycle, recovery was defined by the number of days until neutrophil and platelet counts returned to ≥750 × 10 6 /L and ≥75 × 10 9 /L without ... WebChemotherapy consisted of six cycles of CAPOX (capecitabine 1000 mg/m 2 orally twice daily on days 1–14, oxaliplatin 130 mg/m 2 intravenously on day 1, and a chemotherapy-free interval between days 15–21) or nine cycles of FOLFOX4 (oxaliplatin 85 mg/m 2 intravenously on day 1, leucovorin [folinic acid] 200 mg/m 2 intravenously on days 1 and ... buster beans shirt
Hyperthermic Intraperitoneal Chemotherapy and Interval …
WebApr 13, 2024 · Intracranial Progress Free Survival rate [ Time Frame: 24 months ] ... Patients with non-metastatic diseases who have received neoadjuvant chemotherapy, adjuvant chemotherapy or radiotherapy must experience a no-treatment interval of at least 6 months since the last chemotherapy and/or radiotherapy. Steroid therapy … WebJul 15, 2024 · Patients were stratified by prior (neo)adjuvant therapy, chemotherapy-free interval, and tumor immunohistochemistry PTEN status, and were randomized 1:1 to paclitaxel 80 mg/m 2 (days 1, 8, 15) plus ipatasertib 400 mg or placebo (days 1–21) every 28 days until disease progression or unacceptable toxicity. OS (intent-to-treat ... WebJan 29, 2024 · Optimizing First-Line Therapy in mCRC. EP: 4. Maintenance or Chemo-Free Interval in mCRC. EP: 5. Therapy After Progression in mCRC. EP: 6. Regorafenib in Third or Fourth Line for mCRC: Efficacy in ... buster bear cartoon